Cancer vaccine trial for pseudomyxoma peritonei
Treatments studied
Part of Cancer clinical trials.
This trial tests a vaccine for people with a rare abdominal cancer called pseudomyxoma peritonei (PMP) that has come back or cannot be removed by surgery. The vaccine is designed to help the immune system fight the cancer. It is for people whose tumor has a specific genetic change (GNAS mutation) and who have no other standard treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have pseudomyxoma peritonei (PMP) that has come back or cannot be removed, and no other treatments expected to work.
- Your tumor must have a specific genetic change called a GNAS mutation.
- You must be well enough to have small tissue samples (biopsies) taken from the tumor in your abdomen.
- Your blood counts, kidney function, and liver function must be within certain safe levels.
- You must be able to care for yourself (ECOG score of 0 or 1).
- You must not be pregnant or breastfeeding, and you must use effective birth control during the study and for 6 months after.
- You cannot have other active cancers (except some minor skin or cervical cancers), active infections like hepatitis or HIV, or autoimmune diseases that could flare up.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a chemotherapy combination (capecitabine and cyclophosphamide) given before surgery for people with a large amount of pseudomyxoma peritonei (PMP). The goal is to see if it can shrink the tumor and make surgery more effective.
This trial tests if an intestinal or multi-organ transplant can help people with a rare, widespread abdominal cancer called pseudomyxoma peritonei that cannot be removed by standard surgery. The goal is to remove all visible cancer and replace affected organs with a donated transplant.
This trial compares a lower dose of heated chemotherapy (HIPEC) given during surgery to a standard dose for patients with pseudomyxoma peritonei (a condition where jelly-like mucus builds up in the abdomen). The goal is to see if the lower dose works just as well with fewer side effects.
This trial tests whether the drug metformin (a common diabetes pill) can help control pseudomyxoma peritonei, a rare abdominal cancer. It is for people whose cancer has come back or cannot be surgically removed, and who aren't planning a major surgery with heated chemotherapy at this time.
This Phase 1/2 trial tests a cancer vaccine (TG01/QS-21) in people with high-risk smoldering multiple myeloma or multiple myeloma. It aims to see how safe the vaccine is and whether it can help the immune system control the disease.
This trial tests a new immunotherapy vaccine called PVX7 for women with advanced cervical cancer that is caused by HPV. It aims to see if the vaccine can help prevent the cancer from coming back after standard treatment.
Hear when a new Pseudomyxoma Peritonei trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.